U.S. markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.09
    +0.45 (+0.99%)
     
  • Gold

    1,842.00
    +0.90 (+0.05%)
     
  • Silver

    24.32
    +0.18 (+0.76%)
     
  • EUR/USD

    1.2127
    -0.0022 (-0.18%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • GBP/USD

    1.3438
    -0.0015 (-0.11%)
     
  • USD/JPY

    104.1400
    +0.2800 (+0.27%)
     
  • BTC-USD

    19,122.84
    +74.55 (+0.39%)
     
  • CMC Crypto 200

    365.19
    -14.05 (-3.71%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Adamis Pharmaceuticals: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Adamis Pharmaceuticals (NASDAQ:ADMP) decreased 2.1% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share increased 16.67% year over year to ($0.10), which missed the estimate of ($0.05).

Revenue of $4,301,000 decreased by 27.14% from the same period last year, which missed the estimate of $6,980,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Adamis Pharmaceuticals hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Nov 09, 2020

View more earnings on ADMP

Time: 05:00 PM

ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1398448&tp_key=ef667f9a73

Price Action

Company's 52-week high was at $1.51

52-week low: $0.27

Price action over last quarter: down 29.31%

Company Profile

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company. It is focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy, and opioid overdose. Its SYMJEPI (epinephrine) Injection products are used in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis is developing additional products, including a naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose, and other products for the treatment of asthma and COPD. Its subsidiary compounds sterile prescription drugs, and certain nonsterile drugs for use by hospitals, clinics, and surgery centers throughout the U.S.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.